Vitamin D3 for Life

Live Enlightened

Research libraryVitamin D3 For Life
Study design and methods

Primary relevance to vitamin D Vitamin D is a stated subject of this paper.

Vitamin D is a stated subject of this paper; the supporting source evidence is shown below.

Why this paper is included

Supporting source evidence:

Background: The aim of this study is to evaluate the clinical efficacy of vitamin D (VitD) supplementation in terms of response to treatment and improvement of disease activity in rheumatoid arthritis (RA).

Source: Abstract. View original paper

Relevance classification does not establish study quality, causation or editorial approval.

Study design Study design awaiting verification.

Study design awaiting verification

The available source does not establish a sufficiently clear study design.

Meta-analysis unclear · Blinding unclear / not reported · Human research reported

How this paper was classified

Automatic source-based classification; awaiting editorial verification. This is not a quality score.

All patients were confirmed to have RA according to the 1987 ACR classification criteria and/or the 2010 revised American College of Rheumatology/European League Against Rheumatism classification criteria (), were age ≥ 18 years and were on continued treatment with csDMARDs.

Source: Methods.

View supporting evidence in the original paper

What the study types mean
Systematic review
Uses explicit methods to identify, assess and summarise research on a defined question.
Scoping review
Maps the extent and characteristics of research on a topic.
Narrative review
Discusses existing research; systematic-review methods have not been established by this classification.
Review / evidence synthesis
Reviews existing research; the exact review methods need further assessment.
Randomised controlled trial
Assigns participants or groups to comparison interventions by chance.
Non-randomised intervention study
Examines an intervention without random allocation.
Cohort study
Examines exposures and outcomes over time within a defined group.
Case-control study
Compares people with an outcome against people without it, examining exposures.
Cross-sectional study
Examines a population at a particular point in time.
Observational study
Observes exposures and outcomes without assigning the exposure; the subtype is not established here.
Case report
Describes an individual case.
Case series
Describes a group of individual cases.
Secondary analysis
Analyses existing study data; this paper is not automatically another independent trial.
Laboratory study
Investigates biological processes in a laboratory setting.
Qualitative study
Examines experiences or meanings using qualitative methods.
Genetic instrumental-variable study
Uses genetic variation as an instrument to investigate relationships; this is not a randomised treatment trial.
Study protocol
Describes planned methods and is not evidence that the planned study has reported results.
Multiple reported designs
More than one design is explicitly reported; examine the supporting methods.
Study design awaiting verification
The available source does not establish a sufficiently clear study design.

Meta-analysis combines numerical results from studies. Blinding describes who was unaware of treatment allocation. Neither is a separate quality grade. Study design, vitamin D relevance and document format are independent filters.

Abstracts

The Role of Vitamin D in Combination Treatment for Patients With Rheumatoid Arthritis

Study design awaiting verification · Frontiers in Medicine · 2020

Original publication title

The Role of Vitamin D in Combination Treatment for Patients With Rheumatoid Arthritis

Jianhong Wu; Jianling Dong; Shilin Li; Jiaang Luo; Yu Zhang; Hong Liu; Yuanpiao Ni; Xue Li; Jun Zhou; Hang Yang; Qianrong Xie; Xuejun Jiang; Tingting Wang; Pingxi Wang; Fanwei Zeng; Yanpeng Chu; Jing Yang; Fanxin Zeng

Copyright © 2020 Wu, Dong, Li, Luo, Zhang, Liu, Ni, Li, Zhou, Yang, Xie, Jiang, Wang, Wang, Zeng, Chu, Yang and Zeng.

Original publication · Publisher record · CC BY 4.0

Source wording retained. Formatting, section navigation and display-title punctuation adapted for this research record.

Authors’ conclusion

Conclusion:

VitD supplementation did not provide additional benefit for anti-rheumatic treatment. These data supported the need for prospective, randomized, controlled trials to evaluate the role of VitD supplementation in treating RA.

An extract from the source publication. Read it in context.

At a glance

Abstract: What background does the paper provide?

The aim of this study is to evaluate the clinical efficacy of vitamin D (VitD) supplementation in terms of response to treatment and improvement of disease activity in rheumatoid arthritis (RA).

Source: Background:

Abstract: What methods does the paper describe?

This study analyzed 1180 RA patients' records treated at Mianyang Central Hospital from February 2015 to July 2019. The patients were allocated into VitD group and control group based on their medical regimens. The outcome measures were primary efficacy, defined as treatment response-based EULAR response criteria in RA, and secondary efficacy, defined as improvement in disease activity indicators. Safety was evaluated according to the incidence of all-cause infections.

Source: Methods:

Abstract: Results

At month 6, the primary efficacy revealed that there were 22.8% good responders and 19.0% moderate responders in the VitD group, and 22.3% good responders and 22.3% moderate responders in the control group; there were no differences between the two groups (p = 0.754). The similar primary efficacy outcomes were observed at months 3, 12, and >12. The secondary efficacy indicated that there were no differences in most indexes between the two groups at months 1, 3, 6, 12, and >12. The subgroups (based on baseline DAS28 (CRP), glucocorticoids use and disease duration) analysis results suggested that VitD group didn't have the advantage for treating RA. The incidence of infections was similar in the two groups.

Source: Results:

Abstract: Conclusion

VitD supplementation did not provide additional benefit for anti-rheumatic treatment. These data supported the need for prospective, randomized, controlled trials to evaluate the role of VitD supplementation in treating RA.

Source: Conclusion:
Authors’ abstract

Background:

The aim of this study is to evaluate the clinical efficacy of vitamin D (VitD) supplementation in terms of response to treatment and improvement of disease activity in rheumatoid arthritis (RA).

Methods:

This study analyzed 1180 RA patients' records treated at Mianyang Central Hospital from February 2015 to July 2019. The patients were allocated into VitD group and control group based on their medical regimens. The outcome measures were primary efficacy, defined as treatment response-based EULAR response criteria in RA, and secondary efficacy, defined as improvement in disease activity indicators. Safety was evaluated according to the incidence of all-cause infections.

Results:

At month 6, the primary efficacy revealed that there were 22.8% good responders and 19.0% moderate responders in the VitD group, and 22.3% good responders and 22.3% moderate responders in the control group; there were no differences between the two groups (p = 0.754). The similar primary efficacy outcomes were observed at months 3, 12, and >12. The secondary efficacy indicated that there were no differences in most indexes between the two groups at months 1, 3, 6, 12, and >12. The subgroups (based on baseline DAS28 (CRP), glucocorticoids use and disease duration) analysis results suggested that VitD group didn't have the advantage for treating RA. The incidence of infections was similar in the two groups.

Conclusion:

VitD supplementation did not provide additional benefit for anti-rheumatic treatment. These data supported the need for prospective, randomized, controlled trials to evaluate the role of VitD supplementation in treating RA.

Publication and source details

Original title: The Role of Vitamin D in Combination Treatment for Patients With Rheumatoid Arthritis

Jianhong Wu; Jianling Dong; Shilin Li; Jiaang Luo; Yu Zhang; Hong Liu; Yuanpiao Ni; Xue Li; Jun Zhou; Hang Yang; Qianrong Xie; Xuejun Jiang; Tingting Wang; Pingxi Wang; Fanwei Zeng; Yanpeng Chu; Jing Yang; Fanxin Zeng

Frontiers in Medicine · 2020

Edited by: Kayo Masuko, Sanno Medical Center, Japan

Reviewed by: Hatice Bodur, Ankara Yildirim Beyazit University, Turkey; Cong-Qiu Chu, Oregon Health and Science University, United States

*Correspondence: Jing Yang yangjing6525@163.comFanxin Zeng zengfx@pku.edu.cn

This article was submitted to Rheumatology, a section of the journal Frontiers in Medicine

†These authors have contributed equally to this work

Copyright © 2020 Wu, Dong, Li, Luo, Zhang, Liu, Ni, Li, Zhou, Yang, Xie, Jiang, Wang, Wang, Zeng, Chu, Yang and Zeng.2020Wu, Dong, Li, Luo, Zhang, Liu, Ni, Li, Zhou, Yang, Xie, Jiang, Wang, Wang, Zeng, Chu, Yang and Zenghttps://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

Repository JATS snapshot; version as supplied

Source retrieved: 2026-11-11T16:53:43.212500+00:00

DOI: 10.3389/fmed.2020.00312 · PMC7381115